TAKARA BIO INC.

Business Details

The company's main customers are universities, public research institutions, and pharmaceutical companies. It develops, manufactures, and sells research reagents and instruments based on genetic engineering and cell engineering technologies including PCR/real-time PCR, cloning, stem cells, single-cell analysis, and spatial transcriptome analysis. It also operates GCTP/GMP-compliant contract manufacturing (CDMO) for regenerative medicine-related products, as well as genetic analysis and testing services. The company has manufacturing and sales bases in Japan, the United States, China, and Europe. It is scheduled to become a wholly owned subsidiary of Takara Holdings Inc. in April 2026, following which it will be delisted.

Recent Overview

Revenue declined across all categories and the company fell into an operating loss; an impairment loss of ¥3,876 million was recorded, resulting in a net loss of ¥9,599 million

In FY2026 (ending March 2026), all categories—reagents, instruments, contract services, and gene therapy—posted year-on-year revenue declines, with net sales of ¥40,318 million (down 10.5% year on year). Cost of sales conversely increased 5.7% due to changes in sales composition and other factors, causing gross profit to decline 22.3%. SG&A expenses increased 4.8% due to costs related to the acquisition of Curio Bioscience, Inc. and goodwill amortization, resulting in an operating loss of ¥4,688 million. An impairment loss of ¥3,876 million on idle contract manufacturing facilities and a reversal of deferred tax assets led to a net loss attributable to owners of parent of ¥9,599 million. The tender offer by Takara Holdings was completed, and the company is scheduled to be delisted on June 12, 2026. For FY2027 (ending March 2027), the company forecasts net sales of ¥44,000 million and an operating loss of ¥2,700 million, expecting the loss to narrow.

Key Products

Growth Drivers

• Expected revenue recovery in FY2027 (ending March 2027): projected increases in reagents (¥29,197 million → ¥32,705 million, +12.0%), gene therapy (¥2,932 million → ¥3,496 million, +19.2%), and instruments (¥896 million → ¥1,143 million, +27.6%)
• Entry into the spatial transcriptome analysis field through the acquisition of Curio Bioscience, Inc.: strengthening the product lineup of high-density, high-resolution spatial analysis reagents using proprietary DNA barcode bead technology
• Profit structure reform through becoming a wholly owned subsidiary of Takara Holdings: review of business domains and personnel allocation, streamlining of manufacturing and administrative operations, and faster decision-making by leveraging Takara Holdings' resources and know-how
• Manufacturing facility investment reflected in construction in progress of ¥27,051 million (up ¥7,600 million year on year): potential future expansion of CDMO contract business through enhanced manufacturing capacity
• Relatively steady performance in European sales: ¥5,409 million in FY2026 (ending March 2026), up from ¥5,248 million in the prior period

Risks

• Continued reduction in life science research budgets: the possibility that significant cuts to U.S. government research grants will continue beyond FY2027 (ending March 2027), along with declining R&D activity in industry and academia
• Intensifying competition in the Chinese market: sales sharply declined from ¥8,522 million to ¥5,378 million (down 36.9% year on year) due to intensifying competition with domestic Chinese competitors, with risk of further market share loss
• Low utilization rate in the CDMO business and facility impairment risk: an impairment loss of ¥3,876 million has already been recorded on idle contract manufacturing facilities, and an extraordinary loss of ¥3,208 million is also expected in the FY2027 (ending March 2027) forecast
• Impairment risk on goodwill and technology assets related to the acquisition of Curio Bioscience, Inc.: goodwill of ¥12,432 million and technology assets of ¥11,045 million were recorded (amortized on a straight-line basis over 18 years), with contingent consideration liabilities of ¥9,368 million (current and non-current combined) posing a financial burden
• Sudden changes in the business environment in the Japanese market: declining development projects and changes in development policy at major pharmaceutical companies in the regenerative medicine, cell therapy, and gene therapy fields, and intensifying price competition and new entrants in the genetic analysis field
• Constraints on fundraising methods following delisting: the scheduled delisting on June 12, 2026 will make equity financing impossible, along with the repayment burden of long-term borrowings of ¥10,000 million
• Foreign exchange risk: a high proportion of overseas sales (over 65% of net sales from outside Japan) exposes the company to the impact of yen appreciation on sales and profit